Hepatitis C Patent Challenges In India, Argentina To Allow Generic Production14/02/2017 by Catherine Saez, Intellectual Property Watch Leave a CommentShare this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Google+ (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)IP-Watch is a non-profit independent news service and depends on subscriptions. To access all of our content, please subscribe now. You may also offer additional support with your subscription, or donate.Resistance to high prices for hepatitis C drugs is ongoing as five new challenges against patents have been filed in India and Argentina, according to sources. Those challenges aim at allowing the production and distribution of affordable generic versions of new hepatitis C medicines (direct-acting antivirals). Sofosbuvir tabletAccording to a Médecins Sans Frontières (MSF, Doctors Without Borders) press release, on 13 February the Initiative for Medicines, Access & Knowledge (I-MAK) together with the Delhi Network of Positive People (DNP+), supported by the MSF Access Campaign, filed four cases in India. Two of them are patent challenges on daclatasvir (Bristol-Myers Squibb), one is on velpatasvir (Gilead), and one on sofosbuvir (Gilead), all hepatitis C drugs.Separately, according to the release, in Argentina, the Fundación Grupo Efecto Positivo (FGEP) filed a patent opposition on sofosbuvir with the support of I-MAK.Patents on drugs not only prevent affordable generic versions from being produced or imported, but also restrict progressive innovation that could otherwise benefit patients, the release said, adding that in the case of HIV, patent barriers were overcome to allow generic competition, bringing prices down by 99 percent.“By systematically applying pressure to remove patent and regulatory barriers that stand in the way of production of more affordable generic versions of direct-acting antiviral medicines used to treat hepatitis C, civil society and vulnerable communities have already supported the introduction of generic competition in India and Egypt, where prices dropped to below USD $300 per 12-week treatment last year,” Leena Menghaney, head of South Asia for MSF’s Access Campaign, said in the release.“But the benefits of these price reductions are not available to all those who need treatment, particularly those people living in middle-income countries with high burdens of hepatitis C,” she added.According to the release, Egyptian and Indian generic suppliers “face multiple intellectual property barriers in the registration and export of DAA [direct-acting antiviral] medicines to several middle-income countries. While licensing deals struck between Indian generic companies and pharmaceutical corporations enable access to lower-cost medicines for India and least-developed countries, by far the greatest burden of hepatitis C disease is found in middle-income countries.” Image Credits: lifebeyondhepatitisc.comShare this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Google+ (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)RelatedCatherine Saez may be reached at firstname.lastname@example.org."Hepatitis C Patent Challenges In India, Argentina To Allow Generic Production" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.